Anthriq

Anthriq occupies an infrastructure-oriented position within neurotechnology: it supplies the sensing hardware, device software, signal-processing tools, and SDK layer that researchers and product teams can use to develop brain-computer-interface and human-computer-interaction applications. Its stated Human Body API concept broadens the addressable problem from EEG interpretation alone to multimodal signals from the brain, muscles, and physiological systems. The product set includes a 19-channel Instinct EEG Headset, Instinct OS, the Streams App, a Headset Manager App, and Instinct SDK and APIs. This creates a different emphasis from companies focused exclusively on clinical neurodiagnostics, consumer wellness wearables, or finished BCI applications. Anthriq’s clearest differentiators are its modular, plug-and-play approach, research-grade hardware, C++ and Python developer support, and explicit effort to bridge academic experimentation with deployable products. Its constraints are also visible: public information does not establish scale of adoption, regulatory clearance, recurring revenue, or defensibility through granted patents.

Anthriq’s financing history shows a progression from an angel round in August 2020 to a $1.2 million pre-seed round announced on March 1, 2022, followed by another seed round recorded on January 1, 2023 and a $3.5 million seed round announced on November 7, 2024. The structured funding total is $4.7 million across four rounds, although amounts for the 2020 angel and 2023 seed rounds are not publicly specified. The 2024 financing is the clearest inflection point: it materially increased available capital and was linked to expansion of the company’s brain-computer-interface work. Product development has also moved from a single headset proposition toward an integrated stack comprising Instinct hardware, a Debian-based operating system, visualization and recording software, device management, and SDKs. The January 2026 rebrand from Nexstem to Anthriq suggests a strategic broadening from BCI hardware toward a wider biosignal infrastructure platform. The company reports approximately 11–50 employees in its size band and three highlighted current positions.